title: Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
authors.affiliation: Geriatric VIP Ward, Division of Nursing, Zhejiang University, Hangzhou, People's Republic of China.
authors.forename: Ling-ling
authors.initials: LL
authors.lastname: Zhu
authors.affiliation: Department of Urology Surgery, Zhejiang University, Hangzhou, People's Republic of China.
authors.forename: Zhi-jun
authors.initials: ZJ
authors.lastname: Feng
authors.affiliation: Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhou
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D011799:Quinazolines; D064804:Urological Agents
references.citation: Eur Urol. 2000 Mar;37(3):306-13
references.pmid: 10720857
references.citation: Eur Urol. 1998;33 Suppl 2:7-11
references.pmid: 9556190
references.citation: J Urol. 2006 Oct;176(4 Pt 1):1529-33
references.pmid: 16952675
references.citation: Rev Urol. 2005;7 Suppl 4:S22-30
references.pmid: 16986051
references.citation: BJU Int. 2000 Apr;85 Suppl 2:6-11
references.pmid: 10781179
references.citation: Handb Exp Pharmacol. 2011;(202):283-306
references.pmid: 21290232
references.citation: Int J Urol. 2008 Mar;15(3):193-9
references.pmid: 18304211
references.citation: Expert Opin Drug Saf. 2014 Sep;13(9):1187-97
references.pmid: 25073735
references.citation: Curr Urol Rep. 2005 Jul;6(4):263-70
references.pmid: 15978225
references.citation: J Urol. 2003 Aug;170(2 Pt 1):530-47
references.pmid: 12853821
references.citation: Mayo Clin Proc. 2004 Nov;79(11):1423-34
references.pmid: 15544022
references.citation: Eur Urol. 1999;36 Suppl 3:52-63
references.pmid: 10559631
references.citation: Br J Pharmacol. 1994 Nov;113(3):723-8
references.pmid: 7858860
references.citation: Biol Pharm Bull. 2012;35(1):72-7
references.pmid: 22223340
references.citation: J Urol. 2011 May;185(5):1793-803
references.pmid: 21420124
references.citation: Drugs. 2002;62(4):633-53
references.pmid: 11893233
references.citation: Clin Interv Aging. 2015 Jan 17;10:277-86
references.pmid: 25653511
references.citation: Drugs. 2015 Feb;75(2):207-17
references.pmid: 25575983
references.citation: J Urol. 2008 Mar;179(3):1040-6
references.pmid: 18206918
references.citation: World J Urol. 2002 Apr;19(6):405-412
references.pmid: 28386660
references.citation: Eur Urol. 2013 Jul;64(1):118-40
references.pmid: 23541338
references.citation: Clin Interv Aging. 2011;6:161-72
references.pmid: 21753871
references.citation: Int J Clin Pract. 2013 Jun;67(6):544-51
references.pmid: 23409749
references.citation: BJU Int. 2003 Dec;92(9):876-7
references.pmid: 14632836
references.citation: Anesthesiology. 2005 Aug;103(2):327-34
references.pmid: 16052115
references.citation: Curr Opin Urol. 2012 Jan;22(1):7-15
references.pmid: 22080875
references.citation: J Clin Hypertens (Greenwich). 2014 Jan;16(1):14-26
references.pmid: 24341872
references.citation: Br J Clin Pharmacol. 2011 Aug;72(2):205-17
references.pmid: 21265873